Physician profile
Brandy Long
NPI 1730747593
$4,912.05
in general payments reported to CMS, 2019-2025
14 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $249 · 2023: $1,428 · 2024: $1,526 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,446 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.81 |
| Education | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $917.91 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $675.07 | 2021-2025 | |
| Indivior INC. | $578.50 | 2022-2024 | Perseris |
| Neurocrine Biosciences, INC. | $527.68 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $366.54 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $353.61 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $318.29 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $307.69 | 2021-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $297.98 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $276.20 | 2023-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.54 | 2022-2023 | |
| Lundbeck LLC | $58.81 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $35.80 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $21.43 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.